[Edaily Reporter Na Eun-kyung] #Inventige Lab announced on the 17th that it will participate in the “Bio International Convention 2026” (BioUSA 2026), taking place in San Diego, USA, from the 22nd to the 25th, to discuss business development (BD) and technology partnerships with global pharmaceutical and biotech companies.
Bio USA is a biotech industry partnering event attended by global pharmaceutical and biotech companies, investment firms, and research institutions.
At this event, Inventige Lab plans to hold partnering meetings focused on its long-acting injectable platform, “IVL-DrugFluidic®,” and its subcutaneous (SC) formulation platform for antibody drugs, “IVL-BioFluidic™.”
IVL-DrugFluidic is a long-acting injectable platform that utilizes microfluidics technology to control the rate of drug release. Inventige Lab is using this platform to develop a pipeline of long-acting obesity treatments based on semaglutide and tirzepatide, and plans to discuss opportunities for technology transfer and joint development.
IVL-Biofluidic is a platform designed to enable the development of antibody drugs—which require high-concentration formulations—in subcutaneous injection form. Interest in this technology is growing as there is a rising demand within the global pharmaceutical industry to convert intravenous (IV) antibody therapies to subcutaneous injections.
The company explained that it plans to discuss opportunities for joint research and feasibility evaluations utilizing its ultra-high-concentration particleization technology for antibody drugs at this event.
An Inventige Lab official stated, “Bio USA 2026 is a crucial event for expanding collaboration opportunities with global pharmaceutical companies based on our drug delivery platform technology,” adding, “We plan to strengthen the global competitiveness of our platform technology by broadening commercialization opportunities for IVL-DrugFluidic while actively exploring global co-development possibilities for IVL-BioFluidic.”
Inventige Lab has been participating in Bio USA since 2019, building a network with global pharmaceutical and biotech companies. The company plans to hold approximately 40 partnering meetings at this event and also intends to discuss joint development and business collaboration strategies with its existing partners.
Hyundai MARINE & FIRE INSURANCE CO.,LTD is offering insurance premium discounts to drivers who have installed safety devices to prevent accidental pedal misapplication.
(Photo courtesy of Hyundai M…
As Moderna and Merck’s personalized mRNA cancer vaccines have yielded positive preliminary results in Phase 3 clinical trials, the technological capabilities of NeoGenLogic—a subsidiary of SCL Science…
MARBLEX, a blockchain specialist company affiliated with Netmarble Corporation(251270), announced on the 20th that it has officially launched its new Web3 mobile game, “Pixel Tamers,” globally.
…
